ArticleFolia microbiologica2026
Unveiling the anticancer potential of genus Aerva as therapeutics for CLL (Chronic Lymphocytic Leukemia): from plant to patient.
Article in Folia microbiologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The genus Aervacomprises diverse medicinal plant species traditionally used for various therapeutic purposes, yet their pharmacokinetic and toxicological profiles remain largely uncharacterized. This study aimed to evaluate a library of 125 phytochemicals derived from Aerva species using comprehensive in silico approaches. Drug-likeness, ADME parameters, and toxicity profiles were assessed using SwissADME and ProTox-II platforms. Six compounds (AJ26, AJ30, AJ39, AJ43, AJ47, AJ55) exhibited optimal pharmacokinetic properties, including high gastrointestinal absorption, favorable lipophilicity (log P: 1.54-2.56), and acceptable water solubility. All selected compounds met multiple drug-likeness criteria and showed no PAINS alerts. Toxicity analysis revealed low risk for hepatotoxicity, carcinogenicity, and immunotoxicity. Three GEO datasets (GSE22529, GSE26725 and GSE50006) were examined to investigate their therapeutic relevance in chronic lymphocytic leukemia (CLL). 164 common differentially expressed genes (DEGs) were identified, which were primarily associated with pathways of B-cell activation and immunity. The protein-protein interaction analysis identified the CD22, CD38, and CCR6 as strong hub genes, with CD22 had the highest diagnostic performance (average AUC = 0.939). Molecular docking showed that all the molecules showed good interactions with the corresponding receptors such as AJ26-CD38, AJ30-CD22 and AJ43-CCR6. These findings show that Aerva-derived compounds as interesting candidates for future preclinical development in phytochemical-based therapeutics.
Indexed as
Identifiers
42690606What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.